Free Trial

Evaxion A/S (EVAX) Competitors

Evaxion A/S logo
$2.72 +0.11 (+4.21%)
Closing price 08/4/2025 03:59 PM Eastern
Extended Trading
$2.66 -0.06 (-2.02%)
As of 07:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EVAX vs. LPTX, NERV, EQ, ERNA, BFRG, ALVR, BIVI, FLGC, MTVA, and TXMD

Should you be buying Evaxion A/S stock or one of its competitors? The main competitors of Evaxion A/S include Leap Therapeutics (LPTX), Minerva Neurosciences (NERV), Equillium (EQ), Ernexa Therapeutics (ERNA), Bullfrog AI (BFRG), AlloVir (ALVR), BioVie (BIVI), Flora Growth (FLGC), MetaVia (MTVA), and TherapeuticsMD (TXMD). These companies are all part of the "pharmaceutical products" industry.

Evaxion A/S vs. Its Competitors

Leap Therapeutics (NASDAQ:LPTX) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Leap Therapeutics has a net margin of 0.00% compared to Evaxion A/S's net margin of -316.03%. Leap Therapeutics' return on equity of -162.15% beat Evaxion A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Leap TherapeuticsN/A -162.15% -120.05%
Evaxion A/S -316.03%-532.72%-78.32%

Leap Therapeutics currently has a consensus target price of $3.38, suggesting a potential upside of 840.90%. Evaxion A/S has a consensus target price of $10.00, suggesting a potential upside of 267.65%. Given Leap Therapeutics' higher probable upside, research analysts plainly believe Leap Therapeutics is more favorable than Evaxion A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Leap Therapeutics
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Evaxion A/S
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 7.5% of Leap Therapeutics shares are owned by company insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Leap Therapeutics has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500.

In the previous week, Evaxion A/S had 2 more articles in the media than Leap Therapeutics. MarketBeat recorded 2 mentions for Evaxion A/S and 0 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 0.00 beat Evaxion A/S's score of -0.10 indicating that Leap Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Leap Therapeutics Neutral
Evaxion A/S Neutral

Evaxion A/S has higher revenue and earnings than Leap Therapeutics. Evaxion A/S is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Leap TherapeuticsN/AN/A-$67.56M-$1.70-0.21
Evaxion A/S$3.34M1.14-$10.57M-$1.16-2.34

Summary

Evaxion A/S beats Leap Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Evaxion A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVAX vs. The Competition

MetricEvaxion A/SMEDICAL INFO SYS IndustryMedical SectorNASDAQ Exchange
Market Cap$3.66M$2.06B$5.52B$9.35B
Dividend YieldN/AN/A4.73%4.15%
P/E Ratio-2.3436.9229.1424.41
Price / Sales1.1446.00372.8978.84
Price / CashN/A54.1424.4827.20
Price / Book-2.319.368.515.77
Net Income-$10.57M-$63.67M$3.24B$264.99M
7 Day Performance-7.48%-4.20%0.65%-0.68%
1 Month Performance13.10%4.55%7.97%7.08%
1 Year Performance-78.24%16.36%30.78%23.80%

Evaxion A/S Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVAX
Evaxion A/S
1.832 of 5 stars
$2.72
+4.2%
$10.00
+267.6%
-79.5%$3.66M$3.34M-2.3460Short Interest ↑
LPTX
Leap Therapeutics
1.9145 of 5 stars
$0.34
-5.6%
$3.38
+893.8%
-82.5%$14.91MN/A-0.2040Upcoming Earnings
NERV
Minerva Neurosciences
2.7867 of 5 stars
$2.10
-1.4%
$5.00
+138.1%
-34.7%$14.90MN/A2.569
EQ
Equillium
1.9719 of 5 stars
$0.45
+10.7%
$3.00
+573.2%
-18.5%$14.38M$30.41M-1.1440News Coverage
Upcoming Earnings
Gap Down
ERNA
Ernexa Therapeutics
0.8538 of 5 stars
$1.91
-2.1%
N/A-94.2%$14.36M$580K-0.2310Upcoming Earnings
BFRG
Bullfrog AI
0.7843 of 5 stars
$1.49
-2.0%
N/A-57.4%$14.31M$60K-1.844Upcoming Earnings
ALVR
AlloVir
N/A$2.76
-2.8%
N/A-84.8%$13.92MN/A-0.14110Upcoming Earnings
High Trading Volume
BIVI
BioVie
0.1953 of 5 stars
$7.10
-5.1%
N/A+66.7%$13.91MN/A-0.0910
FLGC
Flora Growth
1.2088 of 5 stars
$0.61
-1.5%
$4.00
+560.2%
+2,228.6%$13.89M$59.51M-0.62280News Coverage
Earnings Report
Upcoming Earnings
Gap Down
MTVA
MetaVia
1.4895 of 5 stars
$0.66
-5.9%
$7.50
+1,030.4%
N/A$13.81MN/A0.008News Coverage
Gap Up
TXMD
TherapeuticsMD
0.6169 of 5 stars
$1.17
-1.7%
N/A-31.3%$13.77M$1.76M0.00420Positive News
Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:EVAX) was last updated on 8/5/2025 by MarketBeat.com Staff
From Our Partners